[go: up one dir, main page]

PE20001600A1 - Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica

Info

Publication number
PE20001600A1
PE20001600A1 PE2000000274A PE0002742000A PE20001600A1 PE 20001600 A1 PE20001600 A1 PE 20001600A1 PE 2000000274 A PE2000000274 A PE 2000000274A PE 0002742000 A PE0002742000 A PE 0002742000A PE 20001600 A1 PE20001600 A1 PE 20001600A1
Authority
PE
Peru
Prior art keywords
nonan
carboxamides
derivatives
carboxylates
diazabicyclo
Prior art date
Application number
PE2000000274A
Other languages
English (en)
Inventor
Alistair Lochead
Thierry Gallet
Samir Jeghan
Patrick Lardenois
Alain Nedelec
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001600A1 publication Critical patent/PE20001600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,4-DIAZABICICLO [3.2.2] NONAN-4-CARBOXILATOS Y CARBOXAMIDAS DE FORMULA (I), DONDE: X ES O, NZ; Z ES H, ALQUILO C1-C6; n ES 0-2; R1-R5 SON H, HALOGENO, TRIFLUOROMETILO, TRIFLUOROMETOXI, CIANO, OH, ALQUILO C1-C6, FENOXI, FENILO, ENTRE OTROS; O R2 Y R3 JUNTOS SON -OCH2O-, -(CH2)4-. LOS DERIVADOS DE 1,4-DIAZABICICLO [3.2.2] NONAN-4-CARBOXILATO Y CARBOXAMIDAS TIENEN AFINIDAD POR LOS RECEPTORES NICOTINICOS QUE CONTIENEN LA SUBUNIDAD ALFA Y PUEDEN SER UTILES PARA TRATAMIENTO O PREVENCION DE LOS DESORDENES A NIVEL DEL SITEMA NERVIOSO CENTRAL O DEL SISTEMA GASTROINTESTINAL
PE2000000274A 1999-03-30 2000-03-30 Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica PE20001600A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903934A FR2791678B1 (fr) 1999-03-30 1999-03-30 Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20001600A1 true PE20001600A1 (es) 2001-04-01

Family

ID=9543787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000274A PE20001600A1 (es) 1999-03-30 2000-03-30 Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica

Country Status (15)

Country Link
US (1) US6987106B1 (es)
EP (1) EP1165559B1 (es)
JP (1) JP4500454B2 (es)
AR (1) AR023188A1 (es)
AT (1) ATE232865T1 (es)
AU (1) AU3301800A (es)
CO (1) CO5180557A1 (es)
DE (1) DE60001451T2 (es)
DK (1) DK1165559T3 (es)
ES (1) ES2192520T3 (es)
FR (1) FR2791678B1 (es)
PE (1) PE20001600A1 (es)
TW (1) TWI221843B (es)
UY (1) UY26082A1 (es)
WO (1) WO2000058311A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534344A (ja) 2000-05-25 2003-11-18 ターガセプト，インコーポレイテッド ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
ATE348829T1 (de) * 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
WO2004076453A1 (en) 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP1697378B1 (en) 2003-12-22 2007-11-21 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
JP2007515480A (ja) * 2003-12-22 2007-06-14 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリンレセプターリガンド
BRPI0506881A (pt) * 2004-02-04 2007-06-26 Neurosearch As derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1742944B1 (en) 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
DE602005025902D1 (de) 2004-10-15 2011-02-24 Neurosearch As Neue azabizyklische arylderivate und medizinische verwendung damit
ATE455776T1 (de) 2004-12-22 2010-02-15 Memory Pharm Corp Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US20090075983A1 (en) * 2006-02-14 2009-03-19 Dan Peters Novel Diazabicycloalkane Derivatives and Their Medical Use
JP2007217370A (ja) * 2006-02-17 2007-08-30 Nard Inst Ltd ポジトロン断層撮影法および該方法に用いるポジトロン放出化合物
EP2029594B1 (en) 2006-05-23 2010-10-20 NeuroSearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008119710A1 (en) * 2007-03-30 2008-10-09 Neurosearch A/S Two-phase test method for characterizing the effect of a chemical compound on a test animal and maze for carrying out the method
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
FR2931823B1 (fr) 2008-06-02 2012-08-17 Sanofi Aventis Sel de fumarate du 1,4-diazabicyclo°3.2.2!nonane-carboxylate de 4-bromophenyle, ses formes cristallines, leur preparation et leur utilisation en therapeutique
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
KR101698250B1 (ko) 2010-05-17 2017-01-19 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
PT2685986T (pt) 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
ATE261443T1 (de) * 1997-06-30 2004-03-15 Targacept Inc 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Also Published As

Publication number Publication date
FR2791678A1 (fr) 2000-10-06
UY26082A1 (es) 2000-10-31
DE60001451T2 (de) 2004-01-15
AR023188A1 (es) 2002-09-04
DE60001451D1 (de) 2003-03-27
AU3301800A (en) 2000-10-16
ATE232865T1 (de) 2003-03-15
JP4500454B2 (ja) 2010-07-14
TWI221843B (en) 2004-10-11
FR2791678B1 (fr) 2001-05-04
JP2002540208A (ja) 2002-11-26
EP1165559A1 (fr) 2002-01-02
CO5180557A1 (es) 2002-07-30
EP1165559B1 (fr) 2003-02-19
WO2000058311A1 (fr) 2000-10-05
US6987106B1 (en) 2006-01-17
DK1165559T3 (da) 2003-06-10
ES2192520T3 (es) 2003-10-16

Similar Documents

Publication Publication Date Title
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
TNSN96075A1 (fr) N-(indole-2-carbonyl) - beta- alaninamides substitues et leurs derives, servant d'agents antidiabetiques
AR029190A1 (es) Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco
DK1140088T3 (da) Orale methylphenidatformuleringer med reguleret/modificeret frigivelse
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
PE20020719A1 (es) Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
EP0975602A4 (en) IMIDAZOLE AND IMIDAZOLE DERIVATIVES AND THEIR USE
PT1274687E (pt) Derivados de 1,2,3,4-tetra-hidroisoquinolina
NZ515705A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
DE60230270D1 (de) 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
NO972324L (no) Orale blandinger inneholdende Ondansetron
ATE275397T1 (de) Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit
SE9904508D0 (sv) New compounds
PE20011114A1 (es) Decahidro-isoquinolinas
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
FI980471L (fi) 1,3-substituoidut sykloalkeenit ja sykloalkaanit keskushermostoon vaikuttavina aineina
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
GB8518658D0 (en) Medicaments
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
AR007352A1 (es) Derivados sustituidos de bencimidazol, proceso para su preparacion, formulacion farmaceutica que los contiene, y uso de dichos derivados para la manufactura de medicamentos
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister

Legal Events

Date Code Title Description
FA Abandonment or withdrawal